Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$2.2MCash on Hand
1.6mo Cash Runway
Follow GOVX by emailGet an email when GOVX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about GOVX, unsubscribe in one click. Privacy
📣 What GOVX Says Is Next
late 2026 · “The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in late 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness.”
Company press release, Oct 27, 2026 · SEC filing
second half of 2026 · “The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness.”
Company press release, Jul 27, 2026 · SEC filing
fourth-quarter · “During the second quarter, GeoVax advanced multiple operational initiatives supporting the expected fourth-quarter initiation of the GEO-MVA pivotal immunobridging study under the expedited regulatory pathway established through formal Scientific Advice discussions with the European Medicines Agency (EMA).”
Company press release, Jul 27, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Shareholder vote GeoVax Labs effected a 1-for-24 reverse stock split, filed November 10, 2026, combining every 24 shares of common stock into one share. No fractional shares were issued, and stockholders' ownership percentages and voting power are unchanged apart from rounding. Form 8-K · SEC filing
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 9, 2026 ·
Leadership Five directors resigned effective October 23, 2026, and the board appointed Shahin Behroyan, independent and not yet on any committee, to fill the vacancy. Tyler O'Brien became interim CEO and Chairman effective November 8, 2026. Form 8-K · SEC filing
Nov 6, 2026 ·
Leadership GeoVax terminated CEO David Dodd effective immediately, treating it as a termination for Cause under his 2018 employment agreement. Dodd remains a director and Chairman, and may dispute the determination, which could trigger severance of three times base salary and bonus plus option acceleration. Form 8-K · SEC filing
Nov 4, 2026 ·
Financing GeoVax Labs filed a registration statement on Form S-1 proposing a securities offering. The filing text provided contains only the XBRL cover data and the registration statement cover page, so offering amounts and price are not included. Form S-1 · SEC filing
Oct 27, 2026 ·
Financing GeoVax entered a $1,000,000 revolving loan agreement with Bowery Consulting Group at 12% interest maturing one year after closing, with no amount borrowed yet. Draws are at the lender's sole discretion and the lender can terminate the commitment. Form 8-K · SEC filing · Press release
Oct 27, 2026 ·
Shareholder vote Stockholders approved issuing up to 11,395,256 shares on exercise of warrants tied to the August 25, 2026 warrant inducement, with 1,492,403 for, 458,659 against and 44,131 abstaining. Form 8-K · SEC filing
Sep 17, 2026 ·
Financing Files a registration statement for GeoVax Labs, a Delaware biotech in Smyrna, Georgia, to register its common stock. The offering amount, price, and terms are not yet stated in this preliminary text. Form S-1 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · Phase 2 · Active Trial · SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not GOVX's own candidates): Fludarabine Phosphate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
GOVX holds $2.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $4M/quarter from operations,
an estimated runway of 1.6 months at that rate (BioRadar estimate, not company guidance).
Share count 544,453 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full GOVX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GOVX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.